Comparison of antiproliferative effect of epigallocatechin gallate when loaded into cationic solid lipid nanoparticles against different cell lines

References

• Akhtar N, Haqqi TM. 2011. Epigallocatechin-3-gallate suppresses the global interleukin-1beta-induced inflammatory response in human chondrocytes. Arthritis Res Ther. 13(3):R93.
   PubMed Web of Science ®Google Scholar
• Andreani T, Kiill CP, Souza A, Fangueiro JF, Fernandes L, Doktorovová S, Santos DL, Garcia ML, Gremião MPD, Souto EB, et al. 2014. Surface engineering of silica nanoparticles for oral insulin delivery: characterization and cell toxicity studies. Colloids Surf B. 123:916–923.
   PubMed Web of Science ®Google Scholar
• Azam S, Hadi N, Khan NU, Hadi SM. 2004. Prooxidant property of green tea polyphenols epicatechin and epigallocatechin-3-gallate: implications for anticancer properties. Toxicol in Vitro. 18(5):555–561.
   PubMed Web of Science ®Google Scholar
• Barras A, Mezzetti A, Richard A, Lazzaroni S, Roux S, Melnyk P, Betbeder D, Monfilliette-Dupont N. 2009. Formulation and characterization of polyphenol-loaded lipid nanocapsules. Int J Pharm. 379(2):270–277.
   PubMed Web of Science ®Google Scholar
• Braicu C, Gherman CD, Irimie A, Berindan-Neagoe I. 2013. Epigallocatechin-3-Gallate (EGCG) inhibits cell proliferation and migratory behaviour of triple negative breast cancer cells. J Nanosci Nanotechnol. 13(1):632–637.
   PubMed Web of Science ®Google Scholar
• Cavet ME, Harrington KL, Vollmer TR, Ward KW, Zhang JZ. 2011. Anti-inflammatory and anti-oxidative effects of the green tea polyphenol epigallocatechin gallate in human corneal epithelial cells. Mol Vis. 17:533–542.
   PubMed Web of Science ®Google Scholar
• Chen N, Bezzina R, Hinch E, Lewandowski PA, Cameron-Smith D, Mathai ML, Jois M, Sinclair AJ, Begg DP, Wark JD, et al. 2009. Green tea, black tea, and epigallocatechin modify body composition, improve glucose tolerance, and differentially alter metabolic gene expression in rats fed a high-fat diet. Nutr Res. 29(11):784–793.
   PubMed Web of Science ®Google Scholar
• Chen L, Yang X, Jiao H, Zhao B. 2002. Tea catechins protect against lead-induced cytotoxicity, lipid peroxidation, and membrane fluidity in HepG2 cells. Toxicol Sci. 69(1):149–156.
   PubMed Web of Science ®Google Scholar
• Doktorovová S, Santos DL, Costa I, Andreani T, Souto EB, Silva AM. 2014. Cationic solid lipid nanoparticles interfere with the activity of antioxidant enzymes in hepatocellular carcinoma cells. Int J Pharm. 471(1–2):18–27.
   PubMed Web of Science ®Google Scholar
• Du GJ, Zhang Z, Wen XD, Yu C, Calway T, Yuan CS, Wang CZ. 2012. Epigallocatechin gallate (EGCG) is the most effective cancer chemopreventive polyphenol in green tea. Nutrients. 4(11):1679–1691.
   PubMed Web of Science ®Google Scholar
• Fangueiro JF, Andreani T, Egea MA, Garcia ML, Souto SB, Silva AM, Souto EB. 2014. Design of cationic lipid nanoparticles for ocular delivery: development, characterization and cytotoxicity. Int J Pharm. 461(1–2):64–73.
   PubMedGoogle Scholar
• Fangueiro JF, Andreani T, Fernandes L, Garcia ML, Egea MA, Silva AM, Souto EB. 2014. Physicochemical characterization of epigallocatechin gallate lipid nanoparticles (EGCG-LNs) for ocular instillation. Colloids Surf B. 123(1):452–460.
   PubMedGoogle Scholar
• Fangueiro JF, Calpena AC, Clares B, Andreani T, Egea MA, Veiga FJ, Garcia ML, Silva AM, Souto EB. 2016. Biopharmaceutical evaluation of epigallocatechin gallate-loaded cationic lipid nanoparticles (EGCG-LNs): In vivo, in vitro and ex vivo studies. Int J Pharm. 502(1–2):161–169.
   PubMed Web of Science ®Google Scholar
• Fangueiro JF, Parra A, Silva AM, Egea MA, Souto EB, Garcia ML, Calpena AC. 2014. Validation of a high performance liquid chromatography method for the stabilization of epigallocatechin gallate. Int J Pharm. 475(1–2):181–190.
   PubMedGoogle Scholar
• Farabegoli F, Papi A, Orlandi M. 2011. (-)-Epigallocatechin-3-gallate down-regulates EGFR, MMP-2, MMP-9 and EMMPRIN and inhibits the invasion of MCF-7 tamoxifen-resistant cells. Biosci Rep. 31(2):99–108.
   PubMed Web of Science ®Google Scholar
• Harris N, Brill E, Shohat O, Prokocimer M, Wolf D, Arai N, Rotter V. 1986. Molecular basis for heterogeneity of the human p53 protein. Mol Cell Biol. 6(12):4650–4656.
   PubMed Web of Science ®Google Scholar
• He C, Li L, Guan X, Xiong L, Miao X. 2017. Mutant p53 gain of function and chemoresistance: the role of mutant p53 in response to clinical chemotherapy. Chemotherapy. 62(1):43–53.
   PubMed Web of Science ®Google Scholar
• Kang HW. 2015. Inhibitory effect of cancer cells proliferation from epigallocatechin-3-O-gallate. J Food Nutr Res. 3(4):281–284.
   Google Scholar
• Khan N, Bharali DJ, Adhami VM, Siddiqui IA, Cui H, Shabana SM, Mousa SA, Mukhtar H. 2014. Oral administration of naturally occurring chitosan-based nanoformulated green tea polyphenol EGCG effectively inhibits prostate cancer cell growth in a xenograft model. Carcinogenesis. 35(2):415–423.
   PubMed Web of Science ®Google Scholar
• Krupkova O, Ferguson SJ, Wuertz-Kozak K. 2016. Stability of (-)-epigallocatechin gallate and its activity in liquid formulations and delivery systems. J Nutr Biochem. 37:1–12.
   PubMed Web of Science ®Google Scholar
• Laurie NA, Donovan SL, Shih C-S, Zhang J, Mills N, Fuller C, Teunisse A, Lam S, Ramos Y, Mohan A, et al. 2006. Inactivation of the p53 pathway in retinoblastoma. Nature. 444(7115):61
   PubMed Web of Science ®Google Scholar
• Lee JH, Moon JH, Kim SW, Jeong JK, Nazim UM, Lee YJ, Seol JW, Park SY. 2015. EGCG-mediated autophagy flux has a neuroprotection effect via a class III histone deacetylase in primary neuron cells. Oncotarget. 6(12):9701–9717.
   PubMedGoogle Scholar
• Lee S, Razqan GSA, Kwon DH. 2017. Antibacterial activity of epigallocatechin-3-gallate (EGCG) and its synergism with β-lactam antibiotics sensitizing carbapenem-associated multidrug resistant clinical isolates of Acinetobacter baumannii. Phytomedicine. 24:49–55.
   PubMed Web of Science ®Google Scholar
• Lewandowska H, Kalinowska M, Lewandowski W, Stępkowski TM, Brzóska K. 2016. The role of natural polyphenols in cell signaling and cytoprotection against cancer development. J Nutr Biochem. 32:1–19.
   PubMed Web of Science ®Google Scholar
• Lim YC, Park HY, Hwang HS, Kang SU, Pyun JH, Lee MH, Choi EC, Kim CH. 2008. (-)-Epigallocatechin-3-gallate (EGCG) inhibits HGF-induced invasion and metastasis in hypopharyngeal carcinoma cells. Cancer Lett. 271(1):140–152.
   PubMed Web of Science ®Google Scholar
• Min KJ, Kwon TK. 2014. Anticancer effects and molecular mechanisms of epigallocatechin-3-gallate. Integr Med Res. 3(1):16–24.
   PubMedGoogle Scholar
• Min SY, Yan M, Kim SB, Ravikumar S, Kwon S-R, Vanarsa K, Kim H-Y, Davis LS, Mohan C. 2015. Green tea epigallocatechin-3-gallate suppresses autoimmune arthritis through indoleamine-2,3-dioxygenase expressing dendritic cells and the nuclear factor, erythroid 2-like 2 antioxidant pathway. J Inflamm. 12(1):53.
   Google Scholar
• Ortiz-López L, Márquez-Valadez B, Gómez-Sánchez A, Silva-Lucero MDC, Torres-Pérez M, Téllez-Ballesteros RI, Ichwan M, Meraz-Ríos MA, Kempermann G, Ramírez-Rodríguez GB. 2016. Green tea compound epigallo-catechin-3-gallate (EGCG) increases neuronal survival in adult hippocampal neurogenesis in vivo and in vitro. Neuroscience. 322:208–220.
   PubMed Web of Science ®Google Scholar
• Oyama J-I, Shiraki A, Nishikido T, Maeda T, Komoda H, Shimizu T, Makino N, Node K. 2017. EGCG, a green tea catechin, attenuates the progression of heart failure induced by the heart/muscle-specific deletion of MnSOD in mice. J Cardiol. 69(2):417–427.
   PubMed Web of Science ®Google Scholar
• Piyaviriyakul S, Shimizu K, Asakawa T, Kan T, Siripong P, Oku N. 2011. Anti-angiogenic activity and intracellular distribution of epigallocatechin-3-gallate analogs. Biol Pharm Bull. 34(3):396–400.
   PubMed Web of Science ®Google Scholar
• Radhakrishnan R, Kulhari H, Pooja D, Gudem S, Bhargava S, Shukla R, Sistla R. 2016. Encapsulation of biophenolic phytochemical EGCG within lipid nanoparticles enhances its stability and cytotoxicity against cancer. Chem Phys Lipids. 198:51–60.
   PubMed Web of Science ®Google Scholar
• Santos IS, Ponte BM, Boonme P, Silva AM, Souto EB. 2013. Nanoencapsulation of polyphenols for protective effect against colon-rectal cancer. Biotechnol Adv. 31(5):514–523.
   PubMed Web of Science ®Google Scholar
• Severino P, Andreani T, Jager A, Chaud MV, Santana MH, Silva AM, Souto EB. 2014. Solid lipid nanoparticles for hydrophilic biotech drugs: optimization and cell viability studies (Caco-2 & HEPG-2 cell lines). Eur J Med Chem. 81:28–34.
   PubMed Web of Science ®Google Scholar
• Shankar S, Marsh L, Srivastava RK. 2013. EGCG inhibits growth of human pancreatic tumors orthotopically implanted in Balb C nude mice through modulation of FKHRL1/FOXO3a and neuropilin. Mol Cell Biochem. 372(1–2):83–94.
   PubMed Web of Science ®Google Scholar
• Shen X, Zhang Y, Feng Y, Zhang L, Li J, Xie YA, Luo X. 2014. Epigallocatechin-3-gallate inhibits cell growth, induces apoptosis and causes S phase arrest in hepatocellular carcinoma by suppressing the AKT pathway. Int J Oncol. 44(3):791–796.
   PubMed Web of Science ®Google Scholar
• Shin YS, Kang SU, Park JK, Kim YE, Kim YS, Baek SJ, Lee SH, Kim CH. 2016. Anti-cancer effect of (-)-epigallocatechin-3-gallate (EGCG) in head and neck cancer through repression of transactivation and enhanced degradation of beta-catenin. Phytomedicine. 23(12):1344–1355.
   PubMed Web of Science ®Google Scholar
• Wang R, Zhou W, Jiang X. 2008. Reaction kinetics of degradation and epimerization of epigallocatechin gallate (EGCG) in aqueous system over a wide temperature range. J Agric Food Chem. 56(8):2694–2701.
   PubMed Web of Science ®Google Scholar
• Wolfram S. 2007. Effects of green tea and EGCG on cardiovascular and metabolic health. J Am Coll Nutr. 26(4):373S–388s.
   PubMed Web of Science ®Google Scholar
• Wolfram S, Raederstorff D, Preller M, Wang Y, Teixeira SR, Riegger C, Weber P. 2006. Epigallocatechin gallate supplementation alleviates diabetes in rodents. J Nutr. 136(10):2512–2518.
   PubMed Web of Science ®Google Scholar
• Xu Y, Ho CT, Amin SG, Han C, Chung FL. 1992. Inhibition of tobacco-specific nitrosamine-induced lung tumorigenesis in A/J mice by green tea and its major polyphenol as antioxidants. Cancer Res. 52(14):3875–3879.
   PubMed Web of Science ®Google Scholar
• Yamakawa S, Asai T, Uchida T, Matsukawa M, Akizawa T, Oku N. 2004. (-)-Epigallocatechin gallate inhibits membrane-type 1 matrix metalloproteinase, MT1-MMP, and tumor angiogenesis. Cancer Lett. 210(1):47–55.
   PubMed Web of Science ®Google Scholar
• Zhong Y, Shahidi F. 2012. Lipophilised epigallocatechin gallate (EGCG) derivatives and their antioxidant potential in food and biological systems. Food Chem. 131(1):22–30.
   Web of Science ®Google Scholar
• Zhou L, Elias RJ. 2013. Antioxidant and pro-oxidant activity of (−)-epigallocatechin-3-gallate in food emulsions: Influence of pH and phenolic concentration. Food Chem. 138(2–3):1503–1509.
   PubMed Web of Science ®Google Scholar